Extranodal Nasal-Type NK/T-Cell Lymphoma Treatment: Analysis from a Multicenter Study.

BACKGROUND

Extranodal natural killer/T-cell lymphoma, nasal type (ENKL), or nasal NK/T-cell lymphoma is the most common cause of the syndrome known as "fatal midline granuloma."

AIM: In this study, we aimed to analyze the treatment outcomes of extranodal natural killer (NK)/T-cell lymphomas.

METHODS

Data of 39 patients from 15 centers were evaluated retrospectively. The characteristics that determine the risk status of the patients, in which treatments they received, and their responses were observed.

RESULTS

Complete response was achieved in 21 patients (53.8%) who received first-line therapy. Median follow-up was 12.5 months (range, 1-60 months) and mortality was 56.4% in patients with highly advanced disease. Median overall survival was 16 (95% CI, 13.07-18.93) months.

CONCLUSION

The prognosis of patients with ENKL has been improved with the use of anthracycline-free treatments, but mortality rates remain high in advanced patients.